Member

Login to your account, make a payment, see benefits and more.

Members

Manage Your Plan

Helpful Tools

Wellcare By Fidelis Care

Members
Providers

Login to your account, download forms, view auth grids and more.

Providers

Provider Resources

About Our Plans

Helpful Tools

Providers
Shop For a Plan

See plan benefits, coverage areas, get a quote and more.

Shop for a Plan

Our Plans

Helpful Tools

Wellcare By Fidelis Care

Shop for a Plan
AAA
HomeMemberHelpful ToolsHealth ResourcesSocial Determinants of HealthGiving Back

Giving Back to Our Communities

Fidelis Care and the Centene Foundation Award $1.1 Million to The Jed Foundation to Protect the Mental Health of New York’s Youth

Funding will help expand emotional well-being resources, educational workshops, and training programs for community-based organizations that foster communities of care statewide

September 20, 2024, NEW YORK CITY —  Fidelis Care, a leading health insurer providing quality, affordable coverage to New Yorkers, and the Centene Foundation, the philanthropic arm of Centene Corporation, announced today a $1.1 million grant to The Jed Foundation (JED), a national nonprofit that protects emotional health and prevents suicide for teens and young adults.

With this grant, JED will expand its current services, providing at least five youth-serving community-based organizations (CBOs) with consultation or strategic planning services, including expert guidance, educational workshops, and training programs, equipping young people with life skills and connecting them to mental health care when they are in distress.

“We are thrilled to support the vital work of The Jed Foundation with this grant,” said Vincent Marchello, Chief Medical Officer at Fidelis Care. “At Fidelis Care, we recognize the importance of mental health services in creating healthier communities. This investment underscores our commitment to ensuring youth and adolescents have access to the critical support they need to thrive.”

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), it is currently estimated that nearly one in five 12- to 17-year-olds in the United States experience a major depressive episode every year, and almost half of teens 13 to 17 say they would seek out professional help only as a last resort. In New York State, the need for enhanced mental health support for school-aged youth is critical: in 2021, 57% of New York 12- to 17-year-olds with depression had not received any care in the last year.

“JED is grateful to Fidelis Care and the Centene Foundation for their commitment to supporting the emotional well-being of New York youth and for providing the resources to help them thrive,” said John MacPhee, JED Chief Executive Officer. “This partnership will allow us to bring JED’s lifesaving work to community-based organizations across the state and help them build on their mental health safety nets and approaches, while positively impacting the lives of thousands of young people.”

The inaugural group of CBOs includes Bottom Line, an organization that partners with degree-aspiring students from first-generation and low-income backgrounds as they get into and through college and launch mobilizing first careers; Hetrick-Martin Institute, which provides free, year-round programs and services for LGBTQIA+ youth and allies aged 13 to 24 in New York City; and Prep for Prep, which provides first-rate educational, leadership development and professional advancement opportunities for young people of color in New York City.

"Through decades of experience at Bottom Line, we have seen that the condition of a student's mental health plays a significant role in their overall journey to becoming a college graduate and professional,” said Sheneita R. Graham, Director of Culturally Responsive Programming at Bottom Line. “Our role at Bottom Line is to build strong relationships that assist us in determining need and connecting students to resources that will help them thrive personally to persist academically. Partnering with The Jed Foundation grants us the opportunity to expertly assess our mental health policies, processes, and resources to ensure we provide our students with thoughtful, high-quality support."

"Hetrick-Martin Institute is pleased to be working with The Jed Foundation to improve our ability to recognize young people in distress and conduct suicide risk assessments," said Bridget Hughes, Chief Program Officer at Hetrick-Martin Institute.

"We are so grateful to The Jed Foundation for hosting two workshops for our incoming college freshmen as part of our annual College Transition Retreat,” said Corey Rhoades, Director of Undergraduate Affairs at Prep for Prep. “The presenters shared their expertise and tailored the sessions in a way that was uniquely relevant and engaging for our students."

To learn more about ways to provide community-based organizations with consulting, evidence-based best practices, and data-driven guidance to protect youth mental health and prevent suicide, visit JED’s website.

Fidelis-JED-Social

Screener Program Provides Support to Families Impacted by Social Determinants of Health

SDoH-chart

Fidelis Care’s innovative SDoH screener program was launched two years ago as a grassroots health equity initiative to address conditions in the environments where people are born, live, work, and play that affect their health, well-being, and quality of life. Social Determinants of Health can affect a wide range of health risks and outcomes – particularly among vulnerable populations and in underserved areas.

The screener enables trained Fidelis Care representatives to assess an individual’s immediate needs and challenges related to SDoH through a brief series of questions covering areas such as access to transportation, food, and secure and safe housing. More than 450,000 Fidelis Care members have participated to date.


Click here to learn more about the different Social Determinants of Health and find available resources.

More News:


Fidelis Care Authorization Grids Effective May 1, 2024
3/29/2024 • Posted by Provider Relations in Provider News

The following sections of the Fidelis Care authorization grids have been updated effective May 1, 2024.

 

The following codes have been added on the Medicaid, Medicare, Essential Plan, and Metal-Level Products Authorization Grids and require prior authorization:

C9166   secukinumab

C9167   apadamtase alfa

C9168   mirikizumab-mrkz

J0177    aflibercept hd

J0589    daxibotulinumtoxina-lanm

J1202    miglustat

J1203    cipaglucosidase alfa-atga

J1323    elranatamab-bcmm

J2277    motixafortide

J2782    avacincaptad pegol

J2801    risperidone (Rykindo)

J3055    talquetamab-tgvs

J7165    prothrombin complex concentrate (Balfaxar)

J9073    cyclophosphamide (ingenus)

J9074    cyclophosphamide (sandoz)

J9075    cyclophosphamide, not otherwise specified

J9248    melphalan (hepzato)

J9249    melphalan (apotex)

J9376    pozelimab-bbfg

Q5133  tocilizumab-bavi (tofidence)

Q5134  natalizumab-sztn (tyruko)

 

The following codes have been added on the Medicare Authorization Grids and require prior authorization:

J0577    buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy 

J0578    buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy

 

Evolent Oncology Program (New Century Health) will require review of the following codes for Medicaid, Medicare, Essential Plans and Metal-Level Products:

J0209    sodium thiosulfate (hope)

J1323    elranatamab-bcmm

J1434    fosaprepitant

J2277    motixafortide

J3055    talquetamab-tgvs

J9073    Injection, cyclophosphamide (ingenus)

J9074    Injection, cyclophosphamide (sandoz)

J9075    Injection, cyclophosphamide, not otherwise specified

J9248    Injection, melphalan (hepzato)

J9249    Injection, melphalan (apotex)

 

Visit:  Authorization Grids


Fidelis Care Authorization Grids Effective May 1, 2024
3/29/2024 • Posted by Provider Relations in Provider News

The following sections of the Fidelis Care authorization grids have been updated effective May 1, 2024.

 

The following codes have been added on the Medicaid, Medicare, Essential Plan, and Metal-Level Products Authorization Grids and require prior authorization:

C9166   secukinumab

C9167   apadamtase alfa

C9168   mirikizumab-mrkz

J0177    aflibercept hd

J0589    daxibotulinumtoxina-lanm

J1202    miglustat

J1203    cipaglucosidase alfa-atga

J1323    elranatamab-bcmm

J2277    motixafortide

J2782    avacincaptad pegol

J2801    risperidone (Rykindo)

J3055    talquetamab-tgvs

J7165    prothrombin complex concentrate (Balfaxar)

J9073    cyclophosphamide (ingenus)

J9074    cyclophosphamide (sandoz)

J9075    cyclophosphamide, not otherwise specified

J9248    melphalan (hepzato)

J9249    melphalan (apotex)

J9376    pozelimab-bbfg

Q5133  tocilizumab-bavi (tofidence)

Q5134  natalizumab-sztn (tyruko)

 

The following codes have been added on the Medicare Authorization Grids and require prior authorization:

J0577    buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy 

J0578    buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy

 

Evolent Oncology Program (New Century Health) will require review of the following codes for Medicaid, Medicare, Essential Plans and Metal-Level Products:

J0209    sodium thiosulfate (hope)

J1323    elranatamab-bcmm

J1434    fosaprepitant

J2277    motixafortide

J3055    talquetamab-tgvs

J9073    Injection, cyclophosphamide (ingenus)

J9074    Injection, cyclophosphamide (sandoz)

J9075    Injection, cyclophosphamide, not otherwise specified

J9248    Injection, melphalan (hepzato)

J9249    Injection, melphalan (apotex)

 

Visit:  Authorization Grids